{
    "2019-02-22": [
        [
            {
                "time": "2018-03-05",
                "original_text": "Merck to Buy Immunotherapy Developer Immune Design for $300M",
                "features": {
                    "keywords": [
                        "Merck",
                        "Immunotherapy",
                        "Immune Design",
                        "Acquisition"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-04-10",
                "original_text": "U.S. Senators launch bipartisan probe into rising insulin prices",
                "features": {
                    "keywords": [
                        "U.S. Senators",
                        "bipartisan",
                        "insulin",
                        "prices"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-05-15",
                "original_text": "ELAN or ZTS: Who Is Expected to Report Faster EPS Growth?",
                "features": {
                    "keywords": [
                        "ELAN",
                        "ZTS",
                        "EPS",
                        "Growth"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "biotechnology"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-06-20",
                "original_text": "Pharma Stock Roundup: MRK Buys IMDZ, FDA Grants Priority Review to Some Candidates",
                "features": {
                    "keywords": [
                        "Pharma",
                        "MRK",
                        "IMDZ",
                        "FDA",
                        "Priority Review"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-07-25",
                "original_text": "Is Eli Lilly and Company’s (NYSE:LLY) Balance Sheet Strong Enough To Weather A Storm?",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "Balance Sheet",
                        "Financial Strength"
                    ],
                    "sentiment_score": 0.3,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-08-30",
                "original_text": "Dow 30 Stock Roundup: WMT Earnings Beat, MRK's Keytruda sBLA Gets Priority Review",
                "features": {
                    "keywords": [
                        "Dow 30",
                        "WMT",
                        "MRK",
                        "Keytruda",
                        "sBLA",
                        "Priority Review"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "retail"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-09-10",
                "original_text": "New Research Coverage Highlights FedEx, Honeywell International, Nielsen Holdings Plc, Changyou, J.B. Hunt Transport Services, and Eli Lilly — Consolidated Revenues, Company Growth, and Expectations for 2019",
                "features": {
                    "keywords": [
                        "FedEx",
                        "Honeywell",
                        "Nielsen",
                        "Changyou",
                        "J.B. Hunt",
                        "Eli Lilly",
                        "Revenues",
                        "Growth",
                        "Expectations"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "transportation",
                        "healthcare",
                        "consumer goods"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-10-15",
                "original_text": "What Pharma Investors Need to Know About Pfizer's Latest Disaster",
                "features": {
                    "keywords": [
                        "Pharma",
                        "Pfizer",
                        "Disaster"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}